



Press Release

### **ENROLLING AUTISM CLINICAL TRIALS**

OU Physician's Child Study Center is now enrolling patients in Phase III clinical trials for CM-AT, a treatment for autism. CM-AT is developed by Curemark LLC, a drug research and development company focused on the treatment of neurological diseases.

CM-AT is based on Curemark's research that showed enzyme deficiencies in autistic children result in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.

OU Physician's Child Study Center is one of 20 sites across the country conducting the CM-AT clinical trials. For information on participating in the trial, contact Brenda or Lora at 405-271-5700 ext. 45167.

#### **Links:**

- [Clinical Trials.gov:](#)
- [Project Poster Ad](#)
- [Newspaper Ad](#)